Rui Yang

发表

miR-122 and miR-197 expressions in hepatic carcinoma patients before and after chemotherapy and their effect on patient prognosis.

Hui Jiang, Gang Zhan, Rui Yang, 2021, American journal of translational research.

A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response

B. Druker, M. Deininger, M. Mauro, 2007, Clinical Cancer Research.

Predictive Value of Tumor Infiltrating Lymphocytes in Neoadjuvant Chemotherapy Treated Breast Cancer: A Meta-Analysis of 8052 Patients

Shujun Wang, Shi-qi Li, Rui Yang, 2020 .

Tumor-infiltrating neutrophils and peripheral neutrophil-to-lymphocyte ratio conversely predicted the prognosis of patients with non-small cell lung cancer.

Chao Ma, Yanguo Liu, Xiuwen Wang, 2022, Cellular immunology.

In Chronic Myeloid Leukemia (CML) Patients with Complete Cytogenetic Response to Imatinib, BCR-ABL Kinase Domain Mutations Are Relatively Rare and Not Consistently Associated with Subsequent Relapse.

B. Druker, M. Heinrich, M. Deininger, 2005 .

Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma

Ni Liu, Wengang Zhang, Xinyu Mu, 2022, Frontiers in Immunology.

Real-world study of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant treatment for patients with HER2-positive breast cancer

Xiaoping Zhou, Xindi Ma, Xiaofei Ren, 2022, Medicine.

Prognostic and Clinical Value of the Systemic Immune-Inflammation Index in Biliary Tract Cancer: A Meta-Analysis

Xiulan Peng, Rui Yang, Xia Wang, 2022, Journal of immunology research.

ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma

Wengang Zhang, Yanguo Liu, X. Shang, 2022, BMC pulmonary medicine.

BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.

B. Druker, M. Mori, M. Deininger, 2006, Blood.

Universal chimeric antigen receptor T cell therapy - The future of cell therapy: A review providing clinical evidence.

Wenxuan Sun, Rui Yang, Zehui Jiang, 2022, Cancer treatment and research communications.

BCR-ABL mRNA Levels At and After the Time of a Complete Cytogenetic Response (CCR) Predict the Duration of CCR In Imatinib-Treated Patients with CML Short title: BCR-ABL mRNA levels predict response duration in CML

B. Druker, M. Mori, M. Deininger, 2006 .